Literature DB >> 20625150

Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii.

Enrique Calvo1, F Javier Pastor, M Mar Rodríguez, Isabel Pujol, Josep Guarro.   

Abstract

We have evaluated the efficacy of posaconazole (PSC), voriconazole (VRC), and amphotericin B (AMB) in a murine model of systemic infection by Cryptococcus gattii using immunocompromised animals and three clinical strains of the fungus. AMB was the most effective drug in prolonging the survival of mice and also in reducing tissue burden in all organs tested. To a lesser degree, VRC at 60 mg/kg of body weight in lung tissue and PSC at 40 mg/kg also in spleen demonstrated good efficacy in reducing the fungal load. The PSC and VRC levels in serum and brain tissue, determined by an agar diffusion bioassay method at 4 h after the last dose of the therapy, were above the corresponding MIC values. However, these drugs were not able to reduce the fungal load in brain tissue. Our results demonstrated that PSC and, to a lesser degree, VRC, have fungistatic activity and potential for the treatment of human pulmonary cryptococcosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20625150      PMCID: PMC2944585          DOI: 10.1128/AAC.00172-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease.

Authors:  G Friese; T Discher; R Füssle; A Schmalreck; J Lohmeyer
Journal:  AIDS       Date:  2001-11-23       Impact factor: 4.177

2.  A T cell-independent protective host response against Cryptococcus neoformans expressed at the primary site of infection in the lung.

Authors:  J O Hill; P L Dunn
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

3.  Voriconazole treatment for less-common, emerging, or refractory fungal infections.

Authors:  John R Perfect; Kieren A Marr; Thomas J Walsh; Richard N Greenberg; Bertrand DuPont; Juliàn de la Torre-Cisneros; Gudrun Just-Nübling; Haran T Schlamm; Irja Lutsar; Ana Espinel-Ingroff; Elizabeth Johnson
Journal:  Clin Infect Dis       Date:  2003-04-22       Impact factor: 9.079

4.  Distribution and activity of amphotericin B in humans.

Authors:  K J Christiansen; E M Bernard; J W Gold; D Armstrong
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

5.  Immune status and risk for infection in patients receiving chronic immunosuppressive therapy.

Authors:  Thomas Glück; Bernhard Kiefmann; Mathias Grohmann; Werner Falk; Rainer H Straub; Jürgen Schölmerich
Journal:  J Rheumatol       Date:  2005-08       Impact factor: 4.666

6.  Cryptococcus neoformans var. gattii meningitis in an HIV-positive patient: first observation in the United Kingdom.

Authors:  N Bodasing; R A Seaton; G S Shankland; D Kennedy
Journal:  J Infect       Date:  2004-10       Impact factor: 6.072

7.  A case of pulmonary cryptococcosis followed by pleuritis in an apparently immunocompetent patient during fluconazole treatment.

Authors:  Koichi Izumikawa; Yong Zhao; Kohei Motoshima; Takahiro Takazono; Tomomi Saijo; Sintaro Kurihara; Shigeki Nakamura; Taiga Miyazaki; Masafumi Seki; Hiroshi Kakeya; Yoshihiro Yamamoto; Katsunori Yanagihara; Yoshitsugu Miyazaki; Tomayoshi Hayashi; Shigeru Kohno
Journal:  Med Mycol       Date:  2008-09       Impact factor: 4.076

8.  Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection.

Authors:  Carolina Serena; F Javier Pastor; Marçal Mariné; M Mar Rodríguez; Josep Guarro
Journal:  J Antimicrob Chemother       Date:  2007-05-04       Impact factor: 5.790

9.  Clinical and epidemiological features of 123 cases of cryptococcosis in Mato Grosso do Sul, Brazil.

Authors:  Andrea de Siqueira Campos Lindenberg; Marilene Rodrigues Chang; Anamaria Melo Miranda Paniago; Márcia dos Santos Lazéra; Paula Maria Frank Moncada; Gisele Facholi Bonfim; Susie Andries Nogueira; Bodo Wanke
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2008 Mar-Apr       Impact factor: 1.846

10.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

View more
  5 in total

1.  Efficacy of posaconazole in murine experimental sporotrichosis.

Authors:  Fabiola Fernández-Silva; Javier Capilla; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

Review 2.  Tissue penetration of antifungal agents.

Authors:  Timothy Felton; Peter F Troke; William W Hope
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

3.  Cladophialophora bantiana osteomyelitis in a renal transplant patient.

Authors:  Stefanie Desmet; Liesbeth Smets; Katrien Lagrou; Inge Derdelinckx; Jeroen Neyt; Johan Maertens; Raf Sciot; Philip Demaerel; Bert Bammens
Journal:  Med Mycol Case Rep       Date:  2016-07-09

Review 4.  Pharmacokinetics and Pharmacodynamics of Posaconazole.

Authors:  Lu Chen; Elke H J Krekels; Paul E Verweij; Jochem B Buil; Catherijne A J Knibbe; Roger J M Brüggemann
Journal:  Drugs       Date:  2020-05       Impact factor: 9.546

5.  Antifungal Drugs: Special Problems Treating Central Nervous System Infections.

Authors:  Elizabeth Dodds Ashley
Journal:  J Fungi (Basel)       Date:  2019-10-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.